Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for patients with significant unmet medical needs. The company's diverse portfolio primarily focuses on neuroscience and oncology, offering established treatments such as Xywav and Xyrem for narcolepsy and idiopathic hypersomnia, and Epidiolex for specific seizure disorders. Jazz also provides critical oncology treatments including Rylaze and Enrylaze for acute leukemias and lymphomas, Zepzelca for advanced small cell lung cancer, and Vyxeos for certain types of acute myeloid leukemia. Beyond its commercialized products, Jazz Pharmaceuticals maintains a robust pipeline of investigational therapies across various stages of development. Key pipeline candidates include zanidatamab for HER2-expressing gastroesophageal adenocarcinoma, and novel agents targeting Parkinson's disease tremor, cancer pathways, and sleep disorders. The company strategically leverages collaborations and licensing agreements with other leading biotechnology firms to enhance its research and development capabilities and expand its therapeutic reach. Jazz Pharmaceuticals operates internationally, with a significant presence in the United States and Europe, aiming to bring life-changing treatments to patients worldwide.